BioUnbound - Oral Thin-Film Peptides Delivery Platform
BioUnbound has developed a patented oral thin-film delivery system that achieves injection-level bioavailability (85-95%) for peptide therapeutics without needles, refrigeration, or preparation. The technology addresses a fundamental barrier in the $40 billion peptide market: 78% of consumers refuse injection-based delivery despite wanting the therapeutic benefits.
Technology Platform:Sublingual thin-film strips dissolve in under 60 seconds, delivering peptides directly through oral mucosa into bloodstream circulation. The platform combines nanoparticle encapsulation with permeation enhancers to bypass gastric degradation and first-pass metabolism. Formulations remain stable at room temperature, eliminating cold-chain requirements that constrain current injectable products.
Intellectual Property:Company claims 10 patents (issued and pending) covering formulation chemistry, manufacturing processes, and novel peptide analogs. Independent verification of patent portfolio status pending.
Initial Products: Six SKUs ready for launch within six months of funding. Products target sports recovery (BPC-157, TB-500), longevity and immunity (Thymosin Alpha-1, Epithalon), cognitive function (Semax), sexual wellness (PT-141), and mitochondrial health (SS-31). Each addresses documented consumer demand currently served exclusively through injections.
Distribution Strategy:Letters of intent with major health networks provide immediate access to 10,000+ practitioners and 12 million annual patient appointments. Additional channels include direct-to-consumer sales, influencer partnerships, affiliate networks, and functional medicine clinics.
Regulatory Pathway:Products positioned as nutraceuticals with structure-function claims under DSHEA framework. No FDA approval required for initial launch, enabling rapid market entry with rigorous quality standards. Option to pursue prescription status for specific therapeutic indications if market dynamics warrant.
Market Opportunity: Current peptide therapeutics market is $40 billion annually, projected to exceed $100 billion within five years. Eliminating injection requirements expands addressable market from approximately 10 million current users to 100+ million health-conscious consumers. Average customer lifetime value of $2,400 supports nine-figure revenue potential.
Capital Requirement: $3 million to complete GMP manufacturing scale-up, launch initial six SKUs, establish distribution partnerships, fund clinical validation studies, and build infrastructure for product expansion. Revenue projections: $20 million Year 1, scaling to $100 million by Year 5.
